A Phase 1b Placebo-controlled, Multi-centre, Randomized, Double-blind Dose Escalation Study to Evaluate the Pharmacokinetics (PK) and Safety of SMT C1100 in Patients With Duchenne Muscular Dystrophy (DMD) Who Follow a Balanced Diet

Trial Profile

A Phase 1b Placebo-controlled, Multi-centre, Randomized, Double-blind Dose Escalation Study to Evaluate the Pharmacokinetics (PK) and Safety of SMT C1100 in Patients With Duchenne Muscular Dystrophy (DMD) Who Follow a Balanced Diet

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Ezutromid (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Pharmacokinetics
  • Sponsors Summit Therapeutics
  • Most Recent Events

    • 22 Jun 2017 According to a Summit Therapeutics media release, data from this trial will be presented at the European Paediatric Neurology Society Congress.
    • 18 Dec 2015 Detailed results presented at the 20th World Muscle Society Congress, as per Summit Therapeutics media release.
    • 30 Sep 2015 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top